Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals

Executive Summary

Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.

Advertisement

Related Content

Should Celgene Succumb To The Charms Of Juno?
Merck KGaA Hopes UK Cancer Charity R&D Pact Will Yield New Assets
Forty Seven's IO Antibody Attracts Two Big Pharma Partners
CSL Looks Beyond Organic Growth To External Innovation
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
China Investment Roundup: Active Deal-Making In Precision Medicine
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Beigene/Boehringer Biomanufacturing Bond Tests China MAH System
Aeterna Zentaris tanks on FDA Macrilen rejection
Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel